JP2024518270A - イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法 - Google Patents

イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法 Download PDF

Info

Publication number
JP2024518270A
JP2024518270A JP2023562616A JP2023562616A JP2024518270A JP 2024518270 A JP2024518270 A JP 2024518270A JP 2023562616 A JP2023562616 A JP 2023562616A JP 2023562616 A JP2023562616 A JP 2023562616A JP 2024518270 A JP2024518270 A JP 2024518270A
Authority
JP
Japan
Prior art keywords
vitamin
subject
inositol
sorbitol
erythritol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518270A5 (enExample
Inventor
チー， ジェイソン チョウ，
シャイレイ， クマール ドグラ，
アドリアン ダルディニエ，
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2024518270A publication Critical patent/JP2024518270A/ja
Publication of JP2024518270A5 publication Critical patent/JP2024518270A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023562616A 2021-05-06 2022-05-04 イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法 Pending JP2024518270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185097P 2021-05-06 2021-05-06
US63/185,097 2021-05-06
PCT/EP2022/061949 WO2022233922A1 (en) 2021-05-06 2022-05-04 Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii

Publications (2)

Publication Number Publication Date
JP2024518270A true JP2024518270A (ja) 2024-05-01
JP2024518270A5 JP2024518270A5 (enExample) 2025-03-05

Family

ID=81941092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562616A Pending JP2024518270A (ja) 2021-05-06 2022-05-04 イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法

Country Status (5)

Country Link
US (1) US20240226030A1 (enExample)
EP (1) EP4333644A1 (enExample)
JP (1) JP2024518270A (enExample)
CN (1) CN117119907A (enExample)
WO (1) WO2022233922A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202316101D0 (en) * 2023-10-20 2023-12-06 Tate & Lyle Solutions Usa Llc Compositions and uses
WO2025083419A1 (en) * 2023-10-20 2025-04-24 Tate & Lyle Solutions Usa Llc Allulose or erythritol for use in improving gut microbiota population and medical treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007051132A (ja) * 2005-07-19 2007-03-01 Hokkaido Sugar Co Ltd イノシトールを成分とする食用組成物または医薬組成物
US20140023701A1 (en) * 2011-04-07 2014-01-23 Nugevity Llc Method and Composition for Ameliorating the Effects tor a Subject Exposed to Radiation or Other Sources of Oxidative Stress
CN108309960A (zh) * 2018-04-24 2018-07-24 温州医科大学附属第医院 肌醇在制备抗炎药物中的应用
JP2020532985A (ja) * 2017-09-07 2020-11-19 スイート センス インコーポレーテッド 低血糖性糖組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544781A1 (en) * 2003-11-04 2005-05-12 Meiji Dairies Corporation Plant-derived .beta.3-adrenergic receptor agonist substances and uses thereof
CN101156867A (zh) * 2007-10-19 2008-04-09 北京协和建昊医药技术开发有限责任公司 茶多酚膜剂及其制备方法
WO2010083227A1 (en) * 2009-01-14 2010-07-22 Nutrafood Nutrients, Inc. Consumable dissolving film comprising active ingredients derived from bacteria and fungi
US20110189318A1 (en) * 2010-01-29 2011-08-04 Misato Sugahara Methods for enhancing the expression of intracellular redox-associated factors
WO2011122879A2 (ko) * 2010-03-31 2011-10-06 (주)아모레퍼시픽 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물
JP2012065607A (ja) * 2010-09-24 2012-04-05 Hirotaro Matsui サプリメント
US20150209383A1 (en) * 2011-11-04 2015-07-30 General Mills, Inc. Methods and compositions for modulating gastrointestinal bacteria to promote health
EP2664606B1 (en) * 2012-04-25 2016-09-14 Ueno Fine Chemicals Industry, Ltd. An inhibitor of the production of advanced glycation end products
MX2015011700A (es) * 2013-03-05 2016-07-20 Univ Groningen Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.
MX374421B (es) * 2014-08-08 2025-03-06 Soc Des Produits Nestle S A Star Mioinositol y uno o más probióticos y sus usos.
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
CN107802576A (zh) * 2016-09-07 2018-03-16 酷美生物科技（上海）有限公司 一种天然动植物细胞补充剂及其制备方法
CN107252112A (zh) * 2017-06-08 2017-10-17 杭州茗朗生物科技有限公司 一种含egcg的片剂
US11484569B2 (en) * 2017-07-13 2022-11-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria
FR3099053B1 (fr) * 2019-07-24 2023-01-20 Inst Nat De La Rech Agronomique Inra Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale
CN110973630A (zh) * 2019-12-20 2020-04-10 美益添生物医药(武汉)有限公司 一种抗肠道衰老的组合物及其应用
CN112402459B (zh) * 2020-10-27 2023-01-31 江南大学 普拉梭菌缓解过敏性哮喘和鼻炎Th2反应中的应用
CN112625964B (zh) * 2020-12-29 2022-08-02 江南大学 一株鼠李糖乳杆菌在预防和缓解溃疡性结肠炎中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007051132A (ja) * 2005-07-19 2007-03-01 Hokkaido Sugar Co Ltd イノシトールを成分とする食用組成物または医薬組成物
US20140023701A1 (en) * 2011-04-07 2014-01-23 Nugevity Llc Method and Composition for Ameliorating the Effects tor a Subject Exposed to Radiation or Other Sources of Oxidative Stress
JP2020532985A (ja) * 2017-09-07 2020-11-19 スイート センス インコーポレーテッド 低血糖性糖組成物
CN108309960A (zh) * 2018-04-24 2018-07-24 温州医科大学附属第医院 肌醇在制备抗炎药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"PURE ENCAPSULATIONS POLYPHENOL NUTRIENTS| HYPOALLERGENIC NUTRIENT DENSE MULTIVITAMIN/MINERAL FORMU, JPN6026015056, 2008, ISSN: 0005844501 *

Also Published As

Publication number Publication date
US20240226030A1 (en) 2024-07-11
CN117119907A (zh) 2023-11-24
EP4333644A1 (en) 2024-03-13
WO2022233922A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US11701397B2 (en) Use of L. reuteri for recovery of microbiota dysbiosis in early life
US10758555B2 (en) Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section
CN109562117A (zh) 具有2FL和LNnT的营养组合物，用于通过作用于肠道微生物群生态失调来预防和/或治疗非轮状病毒腹泻
CN103582426A (zh) 寡糖混合物以及包含该混合物的食品，特别是婴儿配方产品
Wallace Clinical use of probiotics in the pediatric population
US20240226030A1 (en) Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
RU2742510C2 (ru) Питательная композиция для младенцев и/или детей младшего возраста, содержащая олигосахариды
Smilowitz et al. Tolerability and safety of the intake of bovine milk oligosaccharides extracted from cheese whey in healthy human adults
AU2020397225B2 (en) Compositions for use in the reduction of pain and/or perception of pain in infants and young children
CN119817820A (zh) 活性叶酸类物质有助于调节母子肠道菌群的用途
US20240293485A1 (en) Compositions and methods using a combination of at least one fiber and at least one probiotic to improve microbiome resilience
US20240282458A1 (en) Methods of determining and using a microbiome resilience index
CN115835787A (zh) 用以改善胃肠屏障的包含3-羟基丁酸的营养组合物
Calatayud et al. Probiotics in Pediatrics
RU2782199C2 (ru) Питательные композиции с 2fl и lnnt для применения в профилактике и/или лечении не-ротавирусной диареи путем воздействия на дисбиоз кишечной микробиоты
Salvatore et al. Early nutrition and its effect on the development of functional gastrointestinal disorders
CN120917147A (zh) 供使用的组合物
WO2021255228A1 (en) N-acetylspermidine to improve the gastrointestinal barrier
RU2819186C2 (ru) Питательная композиция, содержащая 2'-фукозиллактозу (2'fl), для улучшения барьера желудочно-кишечного тракта
Hania Szajewska et al. The Effect of Bifidobacterium animalis ssp. lactis Supplementation in Preterm Infants: a Systematic Review of Randomized Controlled Trials

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421